Table 3.
Genotype and allele frequency distribution of CYP3A5*3 and COQ in myopathy and tolerant group on atorvastatin treatment.
| Gene (rs number) | Genotype and allele | Atorvastatin |
OR (CI at 95%) | |
|---|---|---|---|---|
| Myopathy (n = 17) | Tolerant (n = 64) | |||
| CYP3A5*3 (rs776746) | TT | 0 (0.00) | 7 (10.94) | 0.9581 (0.34–2.67) |
| TC | 9 (52.94) | 26 (40.63) | ||
| CC | 8 (47.06) | 31 (48.44) | ||
| T | 9 (26.47) | 40 (31.25) | 1.26 (0.54–2.9) | |
| C | 25 (73.53) | 88 (68.75) | ||
| COQ (rs4693075) | GG | 0 (0) | 4 (6.25) | 0.87 (0.29–2.55) |
| GC | 8 (47.06) | 24 (37.50) | ||
| CC | 9 (52.94) | 36 (56.25) | ||
| G | 8 (23.53) | 32 (25.00) | ||
| C | 26 (76.47) | 96 (75.00) | 1.08 (0.44–2.63) | |
| SLCO1B1 (rs4149056) | TT | 14 (82.35) | 61 (95.31) | |
| TC | 03 (17.64) | 03 (4.68) | 4.35 (0.79–23.91) | |
| CC | 0 (0) | 0 (0) | ||
| T | 31 (91.17) | 125 (97.65) | 4.0 (0.77–20.95) | |
| C | 03 (8.82) | 03 (2.34) | ||
OR, odds ratio; CI, class interval.